The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.
(Q27824815)
scientific article
scientific article
Language:
Current Data About
The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.